Friday 6 November 2026 Export AHG’s income statement to Excel — free account

Akso Health Group Sponsored ADR

Akso Health Group Sponsored ADR’s revenue for fiscal 2026 (year ended March 2026) was $13.8 million, down 6.40% from fiscal 2025.

1.30 0.03 −2.26%

Follow AHG

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 5/9
Altman Z: 112.75
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 1,110.00

Revenue ttm 20.14

Net income ttm 15.61

Free cash flow ttm (160.20)

Net debt Q (11.13)

Valuation

P/E 0.00

Forward P/E 0.00

Price / sales 1.05

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.11

Financial health

Current ratio Q 1.53

Debt / equity Q 0.00

Interest coverage Q (14.99)

Growth

Revenue growth Q +263.89%

Operating income growth Q +41.06%

EPS, this year —

EPS, next year A —

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 29.23%

10-year low 10-year high

P/B against its own 10 years 7.82%

10-year low 10-year high

EV/Sales against its own 10 years 39.56%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —
Growth, 2018–22: −100.0%/yr

0.39 ’18
0.00 ’19 −100
0.00 ’20
0.00 ’21
0.00 ’22

paid change on the year, %

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	8	85	176	0
Receivables	8	—	13	1
Inventory	2	0	0	0
Other	—	—	—	176
	20	142	196	190

	2023	2024	2025	2026
Payables	—	—	—	—
ST’ Debt	—	—	—	0
Other	0	0	10	4
	12	4	14	9

Compound Annual Growth %

	10y	5y	3y
Sales	1.52%	51.12%	1.62%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	29.15%	59.97%	173.54%

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	0.01
’25	—	—	—	—	(0.48)
’24	—	—	—	—	(0.20)
’23	—	—	—	—	(0.02)
’22	—	—	—	—	(0.28)
’21	—	—	—	—	(0.71)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	14
’25	—	—	—	—	15
’24	—	—	—	—	2
’23	—	—	—	—	13
’22	—	—	—	—	6
’21	—	—	—	—	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	1	—	(13)
’25	—	—	(5)	—	1
’24	—	—	—	—	1
’23	—	—	—	—	(3)
’22	—	—	—	—	(9)
’21	—	—	—	—	10

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	(174)	—	(188)
’25	—	—	(5)	—	1
’24	—	—	0	—	1
’23	(2)	—	(1)	—	(3)
’22	(9)	—	1	—	(9)
’21	—	—	—	—	10

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Trend	10 yrs	2027e	2028e	2029e	Next 3/yr
												Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	23	107	61	7	2	6	13	2	15	14		(5.5%)	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	10.09	9.63	5.06	(1.90)	(0.08)		(100.1) pt	Powerpack Akso Health Group Sponsored ADR’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	10	77	7	(47)	(31)	(4)	(13)	(9)	(166)	(21)		n/m
	EBT margin, %	44.04	71.36	12.07	(677.90)	(1,770.43)	(66.81)	(99.13)	(376.58)	(1,125.14)	(149.69)		(193.7) pt
	Net income	9	66	6	(47)	(32)	(4)	(13)	(9)	(135)	(19)		n/m
Per share, $
Per share, $	Revenue	1.62	7.15	3.78	0.43	0.11	0.30	0.58	0.05	0.05	0.02		(39.0%)
	Earnings	0.61	4.38	0.33	(4.38)	(0.71)	(0.28)	(0.02)	(0.20)	(0.48)	0.01		(36.6%)
	Cash flow	0.58	5.85	(0.11)	(3.59)	0.62	(0.43)	(0.14)	0.03	0.00	(0.02)		n/m
	Capex	(0.02)	(0.03)	(0.06)	(0.01)	0.00	0.00	0.00	0.00	0.00	(0.24)		+31.7%
	Free cash flow	0.56	5.82	(0.16)	(3.60)	0.62	(0.43)	(0.14)	0.03	0.00	(0.26)		n/m
	Book value	1.67	9.34	7.79	2.96	1.06	0.62	0.39	2.93	0.70	0.25		(19.0%)
	Shares, m	14	15	16	16	16	20	23	47	285	723		+54.9%
Valuation, ×
Valuation, ×	P/E	7.48	7.88	27.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00		4.3
	P/S	0.00	4.79	2.65	1.32	2.56	3.43	0.30	0.92	0.95	1.84		1.9
	P/B	4.99	3.67	1.29	0.20	1.66	2.24	0.67	3.48	0.10	0.19		1.8
	EV/Sales	0.00	3.56	2.04	1.69	3.05	3.28	0.96	1.49	(2.36)	2.51		1.6
	EV/FCF	4.94	3.57	1.37	0.62	0.81	0.65	(1.37)	(2.12)	(3.52)	(0.32)		0.5
Cash, $m
Cash, $m	Operating cash flow	8	88	(2)	(58)	10	(9)	(3)	1	1	(13)		n/m
	Capex	0	0	(1)	0	—	0	—	—	0	(176)		+103.9%
	Free cash flow	8	87	(3)	(58)	10	(9)	(3)	1	1	(188)		n/m
Balance, $m
Balance, $m	Working capital	23	139	71	40	16	12	9	138	182	181		+25.9%
	Net debt	(19)	(133)	(37)	14	(5)	(18)	(8)	(85)	(176)	0		n/m
	Shareholders’ equity	24	140	127	48	17	12	9	138	199	181		+25.5%
Returns, %
Returns, %	ROA	60.40	68.11	3.28	(56.12)	(62.10)	(35.67)	(3.27)	(11.64)	(75.62)	(9.23)		(69.6) pt
	ROIC	145.03	639.06	3.57	(48.36)	(159.07)	0.00	(974.52)	(10.14)	(453.47)	(7.14)		(152.2) pt
	ROE	45.69	80.08	4.15	(81.55)	(106.55)	(114.02)	(12.87)	(12.85)	(79.97)	(9.83)		(55.5) pt
People
People	Employees	295	400	552	182	113	42	12	9	9	12		(29.9%)
	Revenue/emp, $m	0.08	0.27	0.11	0.04	0.02	0.14	1.10	0.27	1.64	1.15		+34.9%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Sep 2019 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MCK McKesson Corporation	$125.0B	27.5×	25.4×	+7.57% (above 0%: growing)	+16.98% (above 0%: growing)	+32.51% (above 0%: growing)	3.57%	1.45%	Compare
COR Cencora, Inc.	$64.8B	18.8×	17.5×	+5.52% (above 0%: growing)	n/m	−7.81% (below 0%: shrinking)	4.08%	1.03%	Compare
CAH Cardinal Health, Inc.	$62.0B	34.5×	24.5×	+5.47% (above 0%: growing)	+26.34% (above 0%: growing)	+10.87% (above 0%: growing)	3.85%	1.12%	Compare
HSIC Henry Schein, Inc.	$9.4B	22.8×	21.3×	+3.95% (above 0%: growing)	+34.81% (above 0%: growing)	−7.09% (below 0%: shrinking)	31.84%	5.56%	Compare
AHG Akso Health Group Sponsored ADR	$1.1B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%
FOCL FocalTherics	$159.3M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$29.2M	— (loss-making)	— (loss-making)	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$23.0M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
YI 111, Inc. Sponsored ADR	$15.5M	— (loss-making)	— (loss-making)	−29.61% (below 0%: shrinking)	n/m	−185.70% (below 0%: shrinking)	5.33%	(0.85%)	Compare
Median of peers	$4.8B	25.1×	22.9×	+5.50%	+26.34%	+1.15%	6.65%	0.09%

All 12 Medical Distribution stocks →